JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.

Clin Cancer Res 2013 Nov 30;19(22):6230-41. Epub 2013 Sep 30.

Authors' Affiliations: Disease Area Oncology and Preclinical Safety, Discovery and Investigative Pathology, Novartis Institutes for BioMedical Research, Basel, Switzerland.

Purpose: The myeloproliferative neoplasm myelofibrosis is characterized by frequent deregulation of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling, and JAK inhibitors were shown to reduce splenomegaly and ameliorate disease-related symptoms. However, the mutant clone and bone marrow fibrosis persist in the majority of patients. Using preclinical models, we explored whether JAK and pan-deacetylase inhibitor combination yielded additional benefits.

Experimental Design: The combination of the JAK1/2 inhibitor ruxolitinib and panobinostat was investigated using two different mouse models of JAK2(V617F)-driven disease. A Ba/F3 JAK2(V617F) cell-driven leukemic disease model was used to identify tolerated and efficacious doses. The drugs were then evaluated alone and in combination in a mouse model of myeloproliferative neoplasm-like disease based on transplantation of bone marrow transduced with a retrovirus expressing JAK2(V617F). Exposures were determined in blood and tissues, and phosphorylated STAT5 and acetylated histone H3 pharmacodynamic readouts were assessed in spleen and bone marrow. Histologic analysis was conducted on spleen and bone marrow, including staining of reticulin fibers in the latter organ.

Results: The combination of ruxolitinib and panobinostat was found to have a more profound effect on splenomegaly, as well as on bone marrow and spleen histology, compared with either agent alone, and the analysis of pharmacodynamic readouts showed that ruxolitinib and panobinostat have nonoverlapping and complementary effects.

Conclusion: Combining JAK1/2 and pan-deacetylase inhibitors was fairly well tolerated and resulted in improved efficacy in mouse models of JAK2(V617F)-driven disease compared with the single agents. Thus, the combination of ruxolitinib and panobinostat may represent a promising novel therapeutic modality for myeloproliferative neoplasms.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0905DOI Listing
November 2013
28 Reads

Publication Analysis

Top Keywords

bone marrow
20
ruxolitinib panobinostat
16
jak2v617f-driven disease
12
models jak2v617f-driven
12
mouse models
12
combination ruxolitinib
8
improved efficacy
8
jak1/2 pan-deacetylase
8
pharmacodynamic readouts
8
pan-deacetylase inhibitor
8
spleen bone
8
inhibitor combination
8
combination
6
bone
5
disease
5
marrow
5
majority patients
4
reticulin fibers
4
patients preclinical
4
panobinostat
4

Similar Publications